In Q1 FY2026, PROCEPT BioRobotics reported revenue of $83.1 million, up 20.2% year-over-year. Net loss widened to $31.6 million, a 27.9% increase from the prior year. Operating loss was $32.6 million, up 18.8%. Diluted EPS was -$0.56, compared to -$0.45 a year ago. The company held $245.6 million in cash, $347.7 million in equity, and $51.7 million in long-term debt.
•Revenue grew 20.2% YoY to $83.1 million.
•Net loss increased 27.9% to $31.6 million.
•Operating loss rose 18.8% to $32.6 million.
•Cash position of $245.6 million with $51.7 million in long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
PROCEPT BioRobotics Corporation, a surgical robotics company develops transformative solutions in urology in the United States and globally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia
HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. Incorporated in 2007, PROCEPT BioRobotics is headquartered in San Jose, California.
What does PROCEPT BioRobotics Corporation (PRCT) do?
PROCEPT BioRobotics Corporation is a surgical robotics company focused on developing transformative solutions in urology. The company designs, manufactures, and sells the AquaBeam Robotic System, an image-guided surgical robotic system used for minimally invasive urologic surgery, primarily to treat benign prostatic hyperplasia (BPH). Additionally, it offers the HYDROS Robotic System, which provides Aquablation therapy—an image-guided robotic therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics operates in the United States and globally, aiming to improve outcomes for patients with urological conditions through advanced robotic technology.
Where is PROCEPT BioRobotics (PRCT) listed and in which currency?
PROCEPT BioRobotics Corporation is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol PRCT. The company trades in U.S. dollars (USD), as it is headquartered in the United States. Being listed on a major U.S. exchange provides liquidity and visibility to investors worldwide.
What sector and industry does PROCEPT BioRobotics (PRCT) operate in?
PROCEPT BioRobotics Corporation operates in the Healthcare sector, specifically within the Medical Devices industry. The company focuses on developing surgical robotic systems for urological procedures, making it a key player in the medical device space. Its products, such as the AquaBeam and HYDROS Robotic Systems, are designed for minimally invasive surgeries, aligning with the broader trend toward robotic-assisted surgery in healthcare.
Where is PROCEPT BioRobotics (PRCT) headquartered and what markets does it serve?
PROCEPT BioRobotics Corporation is headquartered in San Jose, California, United States. The company serves both the domestic U.S. market and global markets, as indicated by its operations in the United States and internationally. Its robotic systems are used by urologists worldwide to treat benign prostatic hyperplasia (BPH) and related conditions, leveraging its San Jose base for research, development, and manufacturing.